REVIEW article
Front. Chem.
Sec. Theoretical and Computational Chemistry
Volume 13 - 2025 | doi: 10.3389/fchem.2025.1632046
This article is part of the Research TopicAI for Molecular Design and SynthesisView all 3 articles
Recent Advances in AI-Based Toxicity Prediction for Drug Discovery
Provisionally accepted- 1Chung-Ang University, Seoul, Republic of Korea
- 2Kyung Hee University, Seoul, Republic of Korea
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Toxicity, defined as the potential harm a substance can cause to living organisms, requires the implementation of stringent regulatory standards to ensure public safety. These standards involve comprehensive testing frameworks, including hazard identification, dose-response evaluation, exposure assessment, and risk characterization. In drug discovery and development, these processes are often complex, time-consuming, and also resource-intensive. Toxicity-related failures in the later stages of drug development can lead to substantial financial losses, underscoring the need for reliable toxicity prediction during the early discovery phases. The advent of computational approaches has accelerated a shift toward in silico modeling, virtual screening, and, notably, artificial intelligence (AI) to identify potential toxicities earlier in the pipeline. Ongoing advances in databases, algorithms, and computational power have further expanded AI's role in pharmaceutical research. Today, AI models are capable of predicting wide range of toxicity endpoints, such as hepatotoxicity, cardiotoxicity, nephrotoxicity, neurotoxicity, and genotoxicity, based on diverse molecular representations ranging from traditional descriptors to graph-based methods. This review provides an in-depth examination of AI-driven toxicity prediction, emphasizing its transformative impact on drug discovery and its growing importance in improving safety assessments. Discovery and Development Preclinical Research Clinical Research AI-based Toxicity prediction Database & Dataset In vitro Toxicity assays -hERG binding -Ames test -MTT assay -Micronucleus assay -etc. In vivo Preclinical studies -LD₅₀ -Carcinogenicity test -Developmental and reproductive toxicity -etc. Human Clinical Trials -Adverse Events (AEs) monitoring -Vital signs & lab tests -etc.
Keywords: artificial intelligence, Drug Discovery, Toxicity, In silico methods, Virtual Screening
Received: 20 May 2025; Accepted: 18 Jun 2025.
Copyright: © 2025 Lee, Kim, Kim and Lee. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yoonji Lee, Chung-Ang University, Seoul, Republic of Korea
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.